TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Active-Control, Parallel-Group, 90-Day Safety Study of CG5503 Immediate Release (IR) or Oxycodone IR in Subjects With Chronic Pain From Low Back Pain or Osteoarthritis of the Hip or Knee
Brief Summary: The purpose of this study is to evaluate the safety of CG5503 base Immediate Release(IR) 50 mg or 100 mg taken every 4 to 6 hours as needed over the long-term exposure of 90 days in patients who have chronic pain.


Options:
A: Intervention Type: DRUG; Name: CG 5503;tapentadol; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: OROS Hydromorphone HCI; Assigned to Arm(s): N/A
C: Arm Label: OROS hydromorphone; Type: EXPERIMENTAL; Interventions: Drug: OROS hydromorphone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: OROS hydromorphone; Assigned to Arm(s): OROS hydromorphone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Intervention Type: DRUG; Name: Oxymorphone Extended Release; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Epidural Etanercept in the Treatment of Sciatica
Brief Summary: Tumor necrosis factor (TNF)-alpha has been strongly implicated as a major contributing factor for the development of radiculopathy. In animal studies, the application of TNF-alpha to nerve roots results in pain behavior indicative of radiculopathy. The use of TNF-alpha inhibitors (etanercept and infliximab) have been shown to prevent this pain behavior. Open-label studies in humans have shown both etanercept and infliximab provide excellent, long-term relief in patients with acute radiculopathy from herniated disc. However, a recent placebo-controlled study failed to demonstrate any significant difference from placebo. The investigators have already established the safety of neuraxial etanercept in a trial that has just been completed (not yet published). The objective of this study is to determine whether small doses of epidural etanercept, an anti-TNF-a medication, is an effective treatment for LBP caused by nerve root irritation (i.e., radiculopathy).


Options:
A: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
B: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Rituximab Intravenous Infusion; Type: EXPERIMENTAL; Interventions: Drug: Anti-CD20 (rituximab) | Arm Label: Placebo Intravenous Infusion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Anti-CD20 (rituximab); Assigned to Arm(s): Rituximab Intravenous Infusion | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo Intravenous Infusion
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo (control procedure) | Arm Label: Epidural injection of etanercept; Type: EXPERIMENTAL; Interventions: Drug: epidural injection of etanercept | Intervention Type: DRUG; Name: epidural injection of etanercept; Assigned to Arm(s): Epidural injection of etanercept | Intervention Type: DRUG; Name: placebo (control procedure); Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Probiotic Prophylaxis for Immunosuppressant Associated Diarrhea (IAD) Following Kidney Transplantation: a Single Center Randomized Controlled Trial
Brief Summary: We hypothesize that the administration of a combination of high numbers of probiotic bacteria will maintain normal bowel function and significantly moderate or obviate Immunosuppression Associated Diarrhea following kidney transplantation.


Options:
A: Arm Label: Human Milk Oligosaccharide (HMO); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Human Milk Oligosaccharides (HMO) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Human Milk Oligosaccharides (HMO); Assigned to Arm(s): Human Milk Oligosaccharide (HMO) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: I; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: II; Type: EXPERIMENTAL; Interventions: Drug: Probiotic Supplement | Intervention Type: DRUG; Name: Probiotic Supplement; Assigned to Arm(s): II | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): I
C: Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic; Assigned to Arm(s): Probiotic
D: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Synbiotic | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Control | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Control; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PeRioperative OXygen Fraction - Effect on Surgical Site Infection and Pulmonary Complications After Abdominal Surgery (The PROXI-trial)
Brief Summary: Aim: To investigate the effect of high intra- and postoperative oxygen concentration (80%, as opposed to normally 30%) on surgical wound infection and pulmonary complications after abdominal surgery.

Background: Surgical wound infection is a common and serious complication. Tissue oxygen tension is often low after surgery and the resistance against infection depends on this factor through bacterial killing by neutrophils. Oxygen is a substrate in this reaction, and it is hypothesized that by increasing the arterial oxygen tension, the risk of surgical wound infection is reduced. Previous studies to test this hypothesis have shown entirely different results. Hence, the clinical decision between high and normal oxygen concentration is still controversial.

Primary hypothesis of study: Use of 80% oxygen decreases the incidence of surgical wound infection after abdominal surgery.

Secondary objectives: To investigate the effect 80% oxygen on pulmonary complications (atelectasis, pneumonia, respiratory insufficiency), second operation, mortality and length of postoperative hospitalization and admission to intensive care unit after abdominal surgery.


Options:
A: Arm Label: Oxygen therapy; Type: OTHER; Interventions: Other: Oxygen therapy | Arm Label: No oxygen therapy; Type: OTHER; Interventions: Other: No oxygen therapy | Intervention Type: OTHER; Name: Oxygen therapy; Assigned to Arm(s): Oxygen therapy | Intervention Type: OTHER; Name: No oxygen therapy; Assigned to Arm(s): No oxygen therapy
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): A, B
C: Intervention Type: OTHER; Name: Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg); Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Supplemental oxygen (80% vs. 30%); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Nitrous Oxide; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Post-Traumatic Stress Disorder (PTSD) Treatment in Cardiac Patients
Brief Summary: This study will evaluate the safety and efficacy of cognitive behavioral therapy in treating people who are experiencing post-traumatic stress disorder after a heart attack.


Options:
A: Arm Label: Behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral interventional program | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral interventional program | Intervention Type: BEHAVIORAL; Name: Behavioral interventional program; Assigned to Arm(s): Behavioral intervention, Standard treatment
B: Arm Label: Cognitive behavioral therapy (CBT); Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy (CBT) | Arm Label: Educational session and treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational session and treatment as usual | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): Cognitive behavioral therapy (CBT) | Intervention Type: BEHAVIORAL; Name: Educational session and treatment as usual; Assigned to Arm(s): Educational session and treatment as usual
C: Arm Label: Referred Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy, Drug: Sertraline, citalopram, or bupropion | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): Stepped Care | Intervention Type: DRUG; Name: Sertraline, citalopram, or bupropion; Assigned to Arm(s): Stepped Care | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Referred Care
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal behavioral intervention | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control intervention | Intervention Type: BEHAVIORAL; Name: Minimal behavioral intervention; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: Control intervention; Assigned to Arm(s): Control group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Otitis and Literacy and Attention at 9 to 11 Years
Brief Summary: Middle-ear disease (infection and fluid) is the most common illness in young children after the common cold. Because hearing loss accompanies middle-ear disease, and because early life is a period of rapid development, concern has existed that sustained periods of middle-ear disease might cause lasting impairments of learning, speech development, language development, or behavior and social adjustment. Earlier phases of this research found that the insertion of ear tubes in children younger than 3 years of age with persistent middle-ear disease did not affect their development at 3, 4, or 6 years of age. This study examines the children's literacy, attention, and related abilities at 9 to 11 years of age.


Options:
A: Intervention Type: PROCEDURE; Name: Insertion of tympanostomy tubes; Assigned to Arm(s): N/A
B: Arm Label: Ventilation tube treatment; Type: EXPERIMENTAL; Interventions: Device: Ventilation tube treatment | Arm Label: Conservative treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Ventilation tube treatment; Assigned to Arm(s): Ventilation tube treatment
C: Intervention Type: PROCEDURE; Name: adenoidectomy and tymapanostomy; Assigned to Arm(s): N/A
D: Arm Label: Triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Triamcinolone acetonide nasal spray | Arm Label: Placebo; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo nasal spray | Intervention Type: DRUG; Name: Triamcinolone acetonide nasal spray; Assigned to Arm(s): Triamcinolone acetonide | Intervention Type: DRUG; Name: Placebo nasal spray; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Otitis and Literacy and Attention at 9 to 11 Years
Brief Summary: Middle-ear disease (infection and fluid) is the most common illness in young children after the common cold. Because hearing loss accompanies middle-ear disease, and because early life is a period of rapid development, concern has existed that sustained periods of middle-ear disease might cause lasting impairments of learning, speech development, language development, or behavior and social adjustment. Earlier phases of this research found that the insertion of ear tubes in children younger than 3 years of age with persistent middle-ear disease did not affect their development at 3, 4, or 6 years of age. This study examines the children's literacy, attention, and related abilities at 9 to 11 years of age.


Options:
A: Intervention Type: PROCEDURE; Name: Insertion of tympanostomy tubes; Assigned to Arm(s): N/A
B: Arm Label: Wait and watch (Group D); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Mometasone spray (Group B); Type: EXPERIMENTAL; Interventions: Drug: Mometasone 50 Mcg/Inh Nasal Spray | Arm Label: antibiotic + histaminic + oxymetazoline drops (Group A); Type: EXPERIMENTAL; Interventions: Drug: Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%) | Arm Label: Oral steroid (Group C); Type: EXPERIMENTAL; Interventions: Drug: Steroid Drug (prednisolone) | Intervention Type: DRUG; Name: Mometasone 50 Mcg/Inh Nasal Spray; Assigned to Arm(s): Mometasone spray (Group B) | Intervention Type: DRUG; Name: Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%); Assigned to Arm(s): antibiotic + histaminic + oxymetazoline drops (Group A) | Intervention Type: DRUG; Name: Steroid Drug (prednisolone); Assigned to Arm(s): Oral steroid (Group C)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxycillin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo equivalent to amoxycillin | Intervention Type: DRUG; Name: Amoxycillin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo equivalent to amoxycillin; Assigned to Arm(s): 2
D: Arm Label: Ventilation tube treatment; Type: EXPERIMENTAL; Interventions: Device: Ventilation tube treatment | Arm Label: Conservative treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Ventilation tube treatment; Assigned to Arm(s): Ventilation tube treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Otitis and Literacy and Attention at 9 to 11 Years
Brief Summary: Middle-ear disease (infection and fluid) is the most common illness in young children after the common cold. Because hearing loss accompanies middle-ear disease, and because early life is a period of rapid development, concern has existed that sustained periods of middle-ear disease might cause lasting impairments of learning, speech development, language development, or behavior and social adjustment. Earlier phases of this research found that the insertion of ear tubes in children younger than 3 years of age with persistent middle-ear disease did not affect their development at 3, 4, or 6 years of age. This study examines the children's literacy, attention, and related abilities at 9 to 11 years of age.


Options:
A: Arm Label: Wait and watch (Group D); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Mometasone spray (Group B); Type: EXPERIMENTAL; Interventions: Drug: Mometasone 50 Mcg/Inh Nasal Spray | Arm Label: antibiotic + histaminic + oxymetazoline drops (Group A); Type: EXPERIMENTAL; Interventions: Drug: Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%) | Arm Label: Oral steroid (Group C); Type: EXPERIMENTAL; Interventions: Drug: Steroid Drug (prednisolone) | Intervention Type: DRUG; Name: Mometasone 50 Mcg/Inh Nasal Spray; Assigned to Arm(s): Mometasone spray (Group B) | Intervention Type: DRUG; Name: Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%); Assigned to Arm(s): antibiotic + histaminic + oxymetazoline drops (Group A) | Intervention Type: DRUG; Name: Steroid Drug (prednisolone); Assigned to Arm(s): Oral steroid (Group C)
B: Intervention Type: PROCEDURE; Name: Insertion of tympanostomy tubes; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxycillin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo equivalent to amoxycillin | Intervention Type: DRUG; Name: Amoxycillin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo equivalent to amoxycillin; Assigned to Arm(s): 2
D: Arm Label: Montelukast; Type: EXPERIMENTAL; Interventions: Drug: Monteleukast | Arm Label: Mometasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Monteleukast; Assigned to Arm(s): Montelukast | Intervention Type: DRUG; Name: Mometasone; Assigned to Arm(s): Mometasone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Otitis and Literacy and Attention at 9 to 11 Years
Brief Summary: Middle-ear disease (infection and fluid) is the most common illness in young children after the common cold. Because hearing loss accompanies middle-ear disease, and because early life is a period of rapid development, concern has existed that sustained periods of middle-ear disease might cause lasting impairments of learning, speech development, language development, or behavior and social adjustment. Earlier phases of this research found that the insertion of ear tubes in children younger than 3 years of age with persistent middle-ear disease did not affect their development at 3, 4, or 6 years of age. This study examines the children's literacy, attention, and related abilities at 9 to 11 years of age.


Options:
A: Arm Label: Triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Triamcinolone acetonide nasal spray | Arm Label: Placebo; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo nasal spray | Intervention Type: DRUG; Name: Triamcinolone acetonide nasal spray; Assigned to Arm(s): Triamcinolone acetonide | Intervention Type: DRUG; Name: Placebo nasal spray; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxycillin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo equivalent to amoxycillin | Intervention Type: DRUG; Name: Amoxycillin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo equivalent to amoxycillin; Assigned to Arm(s): 2
C: Intervention Type: PROCEDURE; Name: Insertion of tympanostomy tubes; Assigned to Arm(s): N/A
D: Arm Label: Ventilation tube treatment; Type: EXPERIMENTAL; Interventions: Device: Ventilation tube treatment | Arm Label: Conservative treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Ventilation tube treatment; Assigned to Arm(s): Ventilation tube treatment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Otitis and Literacy and Attention at 9 to 11 Years
Brief Summary: Middle-ear disease (infection and fluid) is the most common illness in young children after the common cold. Because hearing loss accompanies middle-ear disease, and because early life is a period of rapid development, concern has existed that sustained periods of middle-ear disease might cause lasting impairments of learning, speech development, language development, or behavior and social adjustment. Earlier phases of this research found that the insertion of ear tubes in children younger than 3 years of age with persistent middle-ear disease did not affect their development at 3, 4, or 6 years of age. This study examines the children's literacy, attention, and related abilities at 9 to 11 years of age.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxycillin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo equivalent to amoxycillin | Intervention Type: DRUG; Name: Amoxycillin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo equivalent to amoxycillin; Assigned to Arm(s): 2
B: Intervention Type: PROCEDURE; Name: Insertion of tympanostomy tubes; Assigned to Arm(s): N/A
C: Arm Label: Montelukast; Type: EXPERIMENTAL; Interventions: Drug: Monteleukast | Arm Label: Mometasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Monteleukast; Assigned to Arm(s): Montelukast | Intervention Type: DRUG; Name: Mometasone; Assigned to Arm(s): Mometasone
D: Intervention Type: PROCEDURE; Name: adenoidectomy and tymapanostomy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Parallel-group, Open-label, Multinational Trial Comparing the Safety and Efficacy of Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen, in the Treatment of Pregnant Women With Type 1 Diabetes, Focusing on Maternal Hypoglycaemia and Pregnancy Outcomes
Brief Summary: This trial was conducted in Europe, Middle East, North America and South America.

The aim of this trial was to compare the use of an intensified insulin treatment with insulin aspart (NovoRapid®) versus human insulin (Actrapid®) in pregnancy.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2
B: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
C: Intervention Type: DRUG; Name: human insulin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A
D: Arm Label: Insulin detemir; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir, Drug: insulin aspart | Arm Label: Neutral Protamine Hagedorn (NPH) insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: NPH insulin, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): Insulin detemir | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): Neutral Protamine Hagedorn (NPH) insulin | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): Insulin detemir, Neutral Protamine Hagedorn (NPH) insulin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Parallel-group, Open-label, Multinational Trial Comparing the Safety and Efficacy of Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen, in the Treatment of Pregnant Women With Type 1 Diabetes, Focusing on Maternal Hypoglycaemia and Pregnancy Outcomes
Brief Summary: This trial was conducted in Europe, Middle East, North America and South America.

The aim of this trial was to compare the use of an intensified insulin treatment with insulin aspart (NovoRapid®) versus human insulin (Actrapid®) in pregnancy.


Options:
A: Intervention Type: DRUG; Name: biphasic insulin aspart; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: human insulin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: insulin lispro; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine, Drug: Insulin glulisine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Regular insulin | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Regular insulin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Insulin glulisine; Assigned to Arm(s): 1

Answer: B